Clinical Trial Update: Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer [Phase 3]

View source ↗

Summary

Phase III trial updating patient preference for subcutaneous versus intravenous trastuzumab in HER2-positive advanced breast cancer has completed with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Trastuzumab (trastuzumab)

Snippet

Sponsor: Spanish Breast Cancer Research Group | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2021-02-01